原发性颅内出血周围组织也存在缺血半影区,通过早期神经保护剂干预可被限制。作用于缺血启动的病理生理过程连锁反应诸环节的药物正处于试验及临床评价阶段。设计完善的随机对照试验是评价新药物的有效方法。由于神经保护剂在作用方式、药理性质和不良作用等方面都不同于抗栓和溶栓制剂,因此在设计卒中患者神经保护治疗大样本临床对照试验时必须考虑到许多方法问题。 There are also ischemic penumbra around the primary intracranial hemorrhage, intervention by early neuroprotective agents can be limited. The drugs that act on the links in the pathophysiological process of ischemia-initiated chain reaction are in the experimental and clinical evaluation stage. Well-designed RCTs are an effective way to evaluate new drugs. Because neuroprotective agents are different from antithrombotic and thrombolytic agents in their modes of action, pharmacological properties, and adverse effects, many methodological issues must be considered in the design of neuroprotective large-sample, controlled clinical trials of stroke patients.